FDA: Novo Nordisk failed to report deaths of weight-loss drug patients - USA Today

The FDA determined that Novo Nordisk failed to report patient deaths associated with its weight-loss drugs, a serious regulatory violation that undermines the agency's ability to monitor drug safety. The pharmaceutical company's failure to disclose these adverse events runs counter to federal requirements mandating prompt reporting of deaths potentially linked to medications. This finding raises questions about the company's compliance with post-market surveillance obligations and could trigger FDA enforcement action, including potential fines or restrictions on drug distribution. Novo Nordisk's weight-loss medications, including semaglutide-based products, have become blockbuster drugs globally, making any safety concerns particularly significant given their widespread use.